Potential SP Valuation of AT1 - 80 cents to 1.30/share, page-964

This stock is excellent value at 30c. The company listed at 20c based on the HIV market alone which is enormous without any COVID-19 upside.

The equation is simple. Assuming a blended cost average of $10 per unit x 10 million unit capacity by the end of 2020 = $100M in revenue with 40-60% gross margins.

I like how this company sits in the middle with the IP and manufacturing and partners with third parties with validated immunoassay strips which are easily integrated into the product suite of Atomo.

The French partnership is a great demonstration of their business model. They will be selling COVID-19 antibody tests for the next few years. The fact is, no vaccine against coronavirus has successfully navigated the rigours of clinical testing despite having 17 years to do so. There is a significant medium term opportunity here.

$1 per share does not seem unreasonable by the end of the year with a tight top 20 and Bill Gates Global Health Fund on the register.